- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07789184
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
26 de agosto de 2026 actualizado por: Hua Huang, MD, PhD
A Prospective, Multicenter, Phase III Randomized Controlled Trial Evaluating the Impact of Radical Surgery Versus Non-Surgery on Prognosis and Quality of Life in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy (ALANO Study, CGCA2603 Study)
The goal of this clinical trial is to learn if radical surgery improves prognosis and quality of life compared with continued standard non-surgical treatment in gastric cancer patients with peritoneal metastasis who have achieved successful conversion therapy. The main questions it aims to answer are:
- Does radical surgery prolong overall survival in patients who achieve successful conversion therapy?
- Does radical surgery provide better or at least comparable quality of life and safety outcomes compared with continued standard treatment? Researchers will compare radical surgery versus continued standard systemic treatment to see whether radical surgery provides superior clinical benefit for patients after successful conversion therapy.
Participants will:
- Initial laparoscopic exploration confirms CY0P1 or CY1P1, absence of distant organ metastasis, a PCI ≤ 20, and presence or absence of ascites.
- Receive conversion therapy (chemotherapy, targeted/immunotherapy, intraperitoneal therapy, etc.) per standard guidelines, tailored to the patient's condition and molecular-pathological profile
- If clinical conversion is confirmed, undergo a second laparoscopic exploration to verify successful conversion
- If successful conversion is confirmed (peritoneal lesions cleared or markedly regressed with negative biopsy, no ascites or distant metastases, R0-resectable primary tumor, and improved patient condition), be randomized 1:1 to either the surgery group or the standard treatment group
- In the surgery group, undergo curative gastrectomy with D2 lymphadenectomy during the second laparoscopy, followed by adjuvant therapy and maintenance treatment
- In the standard treatment group, continue systemic therapy without surgery, with maintenance treatment and salvage surgery permitted if clinically indicated
- Complete quality of life questionnaires at predefined time points
- Be followed up for survival, disease progression, adverse events and medical resource use outcomes
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Tipo de estudio
Intervencionista
Inscripción (Estimado)
170
Fase
- Fase 3
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Hua Huang
- Número de teléfono: +86-13816151816
- Correo electrónico: huahuang@fudan.edu.cn
Ubicaciones de estudio
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Porcelana, 100853
- Chinese PLA General Hospital
-
Contacto:
- xiaohui du
- Número de teléfono: +86 010-68182255
- Correo electrónico: duxiaohui301@sina.com
-
Beijing, Beijing Municipality, Porcelana, 102206
- Peking University International Hospital
-
Contacto:
- ning ning
- Número de teléfono: +86 010-69006666
- Correo electrónico: ningning301@126.com
-
Beijing, Beijing Municipality, Porcelana, 100142
- Peking University Cancer Hospital
-
Contacto:
- ziyu li
- Número de teléfono: +86 010-88121122
- Correo electrónico: ziyu_li@hsc.pku.edu.cn
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Porcelana, 400038
- The First Affiliated Hospital of Army Medical University
-
Contacto:
- yan shi
- Número de teléfono: +86 023-68765109
- Correo electrónico: shiyanpwk@tmmu.edu.cn
-
-
Fujian
-
Zhangzhou, Fujian, Porcelana, 363000
- Zhangzhou Affiliated hospital of Fujian Medical University
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana, 510060
- Sun Yat-sen University Cancer Center
-
Contacto:
- huiyan luo
- Número de teléfono: +86 020-87343571
- Correo electrónico: luohy@sysucc.org.cn
-
Guangzhou, Guangdong, Porcelana, 510515
- Nanfang Hospital, Southern Medical University
-
Contacto:
- yanfeng hu
- Número de teléfono: +86 020-61641888
- Correo electrónico: banby@smu.edu.cn
-
Guangzhou, Guangdong, Porcelana, 510655
- The Sixth Affiliated Hospital, Sun Yat-sen University
-
Contacto:
- shi chen
- Número de teléfono: +86 020-38254000
- Correo electrónico: chensh47@mail.sysu.edu.cn
-
-
Hubei
-
Wuhan, Hubei, Porcelana, 430030
- Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
-
Contacto:
- guihua wang
- Número de teléfono: +86 027-83665555
- Correo electrónico: ghwang@tjh.tjmu.edu.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, Porcelana, 210029
- Jiangsu Province Hospital
-
Contacto:
- hao xu
- Número de teléfono: +86 025-83718836
- Correo electrónico: hxu@njmu.edu.cn
-
Nanjing, Jiangsu, Porcelana, 210009
- Jiangsu Cancer Hospital
-
Contacto:
- chao yue
- Número de teléfono: +86 025-83283597
- Correo electrónico: yuechaomeng@126.com
-
Nanjing, Jiangsu, Porcelana, 210008
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School
-
Contacto:
- jia wei
- Número de teléfono: +86 025-83106666
- Correo electrónico: jiawei99@nju.edu.cn
-
Nantong, Jiangsu, Porcelana, 226001
- Nantong First People's Hospital
-
Contacto:
- shichun feng
- Número de teléfono: +86 0513-81111888
- Correo electrónico: fsc2200@126.com
-
-
Jiangxi
-
Nanchang, Jiangxi, Porcelana, 330006
- The First Affiliated Hospital of Nanchang University
-
Contacto:
- zhengrong li
- Número de teléfono: +86 0791-88692748
- Correo electrónico: lzr13@foxmail.com
-
Nanchang, Jiangxi, Porcelana, 330006
- The Second Affiliated Hospital of Nanchang University
-
Contacto:
- bin lai
- Número de teléfono: +86 0791-86120120
- Correo electrónico: Vincent83126@163.com
-
Shangrao, Jiangxi, Porcelana, 334000
- Shangrao People's Hospital
-
Contacto:
- jinqiang chen
- Número de teléfono: +86 0793-8100469
- Correo electrónico: CJQ760624@126.com
-
-
Jilin
-
Changchun, Jilin, Porcelana, 130021
- The First Hospital of Jilin University
-
Contacto:
- quan wang
- Número de teléfono: +86 0431-88782222
- Correo electrónico: wquan@jlu.edu.cn
-
-
Liaoning
-
Dalian, Liaoning, Porcelana, 116011
- The First Affiliated Hospital of Dalian Medical University
-
Contacto:
- pin liang
- Número de teléfono: +86 0411-83635963
- Correo electrónico: sunnyliangpin@163.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Porcelana, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Contacto:
- peng xia
- Número de teléfono: +86 029-85323200
- Correo electrónico: peng_xia666@126.com
-
Xi'an, Shaanxi, Porcelana, 710038
- The Second Affiliated Hospital of Airforce Military Medical University
-
Contacto:
- nan wang
- Número de teléfono: +86 029-84777777
- Correo electrónico: wangnandoc@fmmu.edu.cn
-
-
Shandong
-
Jinan, Shandong, Porcelana, 250021
- Shandong Provincial Hospital
-
Contacto:
- changqing jing
- Número de teléfono: +86 0531-87938911
- Correo electrónico: jingchangqing@sdfmu.edu.cn
-
Jinan, Shandong, Porcelana, 250014
- The First Affiliated Hospital of Shandong First Medical University
-
Contacto:
- jiankang zhu
- Número de teléfono: +86 0531-89268763
- Correo electrónico: 249217523@qq.com
-
Qingdao, Shandong, Porcelana
- The Affiliated Hospital of Qingdao University
-
Contacto:
- zhaojian niu
- Número de teléfono: +86 0532-82911847
- Correo electrónico: niuzhj@hotmail.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 200032
- Fudan University Shanghai Cancer Center
-
Contacto:
- Hua Huang, MD, PhD
- Número de teléfono: +86-13816151816
- Correo electrónico: huahuang@fudan.edu.cn
-
Investigador principal:
- Hua Huang, MD,PHD
-
Shanghai, Shanghai Municipality, Porcelana
- Shanghai General Hospital
-
Contacto:
- yuan fang
- Número de teléfono: +86 021-63240090
- Correo electrónico: Fangyuan1231@aliyun.com
-
-
Shanxi
-
Changzhi, Shanxi, Porcelana, 046000
- Changzhi People'S Hospital
-
Contacto:
- liang zong
- Número de teléfono: +86 0355-2024990
- Correo electrónico: 250537471@qq.com
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Porcelana, 300060
- Tianjin Medical University Cancer Institute&Hospital
-
Contacto:
- xiangyang yu
- Número de teléfono: +86 022-23109106
- Correo electrónico: yxynankai@126.com
-
-
Xinjiang
-
Ürümqi, Xinjiang, Porcelana, 830011
- Affiliated Cancer Hospital of Xinjiang Medical University
-
Contacto:
- wenbin zhang
- Número de teléfono: +86 0991-7968088
- Correo electrónico: zwb3216@sina.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, Porcelana, 310022
- Zhejiang Cancer Hospital
-
Contacto:
- panpan yu
- Número de teléfono: +86 0571-88122222
- Correo electrónico: yupp0571@163.com
-
Hangzhou, Zhejiang, Porcelana, 310009
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
Contacto:
- jiaqi chen
- Número de teléfono: +86 0571-87783777
- Correo electrónico: 2311046@zju.edu.cn
-
Hangzhou, Zhejiang, Porcelana, 310016
- Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of Medicine
-
Contacto:
- linghua zhu
- Número de teléfono: +86 0571-86090073
- Correo electrónico: 3198020@zju.edu.cn
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
No
Descripción
Inclusion Criteria:
- Patients voluntarily participate in the study, sign the informed consent form, and demonstrate good compliance.
- Age ≥ 18 years and ≤ 70 years.
- Histologically and/or cytologically confirmed gastric cancer.
- No evidence of gastric outlet obstruction or intestinal obstruction.
- No distant metastasis on imaging examination. Initial laparoscopic exploration confirms CY0P1 or CY1P1, without distant organ metastasis, with a recorded peritoneal carcinomatosis index (PCI) ≤ 20, and with either positive or negative ascites. Patients meeting these criteria are eligible for pre-enrollment. Following successful conversion therapy, a second laparoscopic exploration must confirm conversion to CY0P0, with no distant organ metastases and no regional lymph node metastases beyond the second station. Only upon meeting these criteria are patients formally enrolled in the study.
- No prior chemotherapy, targeted therapy, or immunotherapy.
- ECOG performance status score of 0-2.
- Life expectancy ≥ 12 weeks.
- Laboratory requirements: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L, platelet count ≥ 75 × 10⁹/L, hemoglobin ≥ 8 g/dL; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN); total bilirubin ≤ 1.5 × ULN. In the presence of liver metastases, AST and ALT ≤ 5 × ULN; Serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance (CCr) ≥ 60 mL/min; International normalized ratio (INR) ≤ 1.5 × ULN; prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
Exclusion Criteria:
- Initial laparoscopic exploration reveals P0, or either of the two laparoscopic explorations reveals distant organ metastasis or distant lymph node metastasis.
- Prior anticancer therapy, including chemotherapy, targeted therapy, or immunotherapy.
- Hypertension that cannot be adequately controlled with antihypertensive medication (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg).
- Active bleeding or coagulation disorder within 2 months prior to enrollment, bleeding tendency, or ongoing thrombolytic therapy, deemed by the investigator as unsuitable for enrollment.
- Active cardiac disease within 6 months prior to treatment, including myocardial infarction, severe/unstable angina pectoris. Left ventricular ejection fraction (LVEF) < 50% on echocardiography, or poorly controlled arrhythmia.
- Known allergy to immunotherapy agents, chemotherapy agents, or any of their excipients.
- Pregnancy (positive pregnancy test prior to treatment initiation) or breastfeeding.
- Active or uncontrolled severe infection: Severe infection within 4 weeks prior to enrollment (e.g., requiring intravenous antibiotics, antifungals, or antivirals); Known human immunodeficiency virus (HIV) infection; History of clinically significant liver disease, including viral hepatitis. For known hepatitis B virus (HBV) carriers, active HBV infection must be excluded, defined as HBV DNA positive (> 1 × 10⁴ copies/mL or > 2000 IU/mL); Known hepatitis C virus (HCV) infection with positive HCV RNA (> 1 × 10³ copies/mL), or other hepatitis, cirrhosis.
- Urinalysis indicating proteinuria ≥ 2+, with 24-hour urine protein quantification > 1.0 g.
- Any other condition deemed by the investigator as inappropriate for participation in this study.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Surgery Group
|
Patients undergo curative gastrectomy with D2 lymphadenectomy (laparoscopic, robotic, or open) during second-look laparoscopy after successful conversion therapy.
Postoperatively, they receive adjuvant systemic therapy (continuing the preoperative regimen or MDT-modified protocol) for up to 8 cycles total, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal.
|
|
Comparador activo: Standard Treatment Group
|
Patients do not undergo surgery.
They continue the original conversion regimen or an MDT-adjusted systemic therapy for a total of 8 cycles, followed by maintenance therapy for up to 1 year after randomization, or until disease progression, unacceptable toxicity, or withdrawal.
Salvage surgery is permitted if clinically indicated.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Overall Survival (OS)
Periodo de tiempo: Up to 3 years after randomization
|
Up to 3 years after randomization
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Quality of Life (QoL) assessed by EORTC QLQ-C30 questionnaires
Periodo de tiempo: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
|
|
Quality of Life (QoL) assessed by EORTC QLQ-STO22 questionnaires
Periodo de tiempo: Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
Prior to first-look laparoscopy, prior to second-look laparoscopy, 1-month post-randomization, 3-months post-randomization, then every 3-months thereafter up to 3-years after randomization
|
|
|
Pathological Complete Response (pCR) Rate
Periodo de tiempo: At the time of radical surgery
|
At the time of radical surgery
|
|
|
R0 Resection Rate
Periodo de tiempo: At the time of radical surgery
|
At the time of radical surgery
|
|
|
Complication-Free Survival
Periodo de tiempo: Up to 3 years after randomization
|
Up to 3 years after randomization
|
|
|
Major Complication Rate
Periodo de tiempo: Within 30 days and 90 days after surgery
|
Within 30 days and 90 days after surgery
|
|
|
Progression-Free Survival (PFS) and Peritoneal PFS
Periodo de tiempo: Up to 3 years after randomization
|
Up to 3 years after randomization
|
|
|
Time to Peritoneal Re-dissemination
Periodo de tiempo: Up to 3 years after randomization
|
Up to 3 years after randomization
|
|
|
Length of Hospital Stay
Periodo de tiempo: Perioperative period
|
Duration of postoperative hospital stay, calculated from the date of surgical intervention to the date of hospital discharge, only applicable to participants receiving surgical treatment.
|
Perioperative period
|
|
Readmission Rate
Periodo de tiempo: Within 30 days and 90 days post-surgery
|
Within 30 days and 90 days post-surgery
|
|
|
Treatment Interruption Rate
Periodo de tiempo: Within 1-year after randomization
|
Within 1-year after randomization
|
|
|
Direct Medical Costs / Hospitalization Costs
Periodo de tiempo: Baseline through study completion, an average of 3-years post-randomization
|
Direct medical costs are defined as all medical expenses directly related to the patient's care, including hospitalization, surgery, medications, laboratory tests, imaging examinations, and management of complications.
Data will be collected continuously throughout the study period (from baseline until death or study completion) and aggregated at the end of the study.
|
Baseline through study completion, an average of 3-years post-randomization
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Estimado)
1 de octubre de 2026
Finalización primaria (Estimado)
1 de octubre de 2031
Finalización del estudio (Estimado)
1 de octubre de 2031
Fechas de registro del estudio
Enviado por primera vez
23 de agosto de 2026
Primero enviado que cumplió con los criterios de control de calidad
26 de agosto de 2026
Publicado por primera vez (Actual)
27 de agosto de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
27 de agosto de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
26 de agosto de 2026
Última verificación
1 de agosto de 2026
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2606346-6-2608A
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Descripción del plan IPD
Individual-participant-level raw data will not be shared externally.
Aggregated study results will be published in peer-reviewed journals.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .